Single Particle Analysis of Viral Nucleic Acid Vectors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for measuring lentivirus titers are cumbersome, inaccurate, and fail to comprehensively reflect the actual titer differences caused by bio-functional differences in lentivirus components, limiting the assessment of viral nucleic acid vector quality in gene therapy.
Innovation Solution
A method involving fluorescence labeling reagents specifically binding to viral nucleic acid vectors, followed by analysis using a flow particle analyzer to detect multiple parameters simultaneously, generating multiple technical and product quality parameters.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional methods (TCID50-GFP fluorescence microscopy, ELISA, quantitative PCR) are used to measure lentivirus titers, then the measurement process can be completed, but the methods are cumbersome, inaccurate, and fail to comprehensively reflect actual titer differences
Solution Approach 1:
The patent segments the viral population into distinct sub-populations based on bio-functional characteristics (e.g., infectious particles vs. non-infectious particles, different viral components). By using flow cytometry to detect and analyze these segmented populations individually, the method achieves precise titer measurement while simplifying the overall process through automated single-particle analysis, resolving the contradiction between measurement precision and process complexity.
Solution Approach 2:
The patent replaces traditional mechanical and manual measurement methods (microscopy, manual ELISA operations, PCR processing) with automated flow cytometry-based single-particle analysis. This substitution enables high-throughput, automated detection of viral particles and their bio-functional characteristics, significantly improving measurement precision while reducing operational complexity and time consumption.
2Measurement precision
If ELISA is used to detect p24 protein content, then the measurement is more accurate and sensitive, but it only measures particle number without determining actual infectivity and overestimates actual viral titer
Solution Approach 1:
The patent employs flow cytometry with multiple fluorescent markers to simultaneously detect and analyze multiple viral characteristics in a single measurement: particle presence, nucleic acid content, protein markers (like p24), and bio-functional infectivity. This multi-functional approach provides comprehensive information about both particle number and actual infectivity, eliminating the loss of information inherent in single-parameter methods like ELISA.
Solution Approach 2:
The patent changes the detection parameters from single-parameter (ELISA detecting only p24 protein concentration) to multi-parameter detection using flow cytometry. By measuring multiple parameters simultaneously (fluorescence intensity, scatter properties, temporal characteristics), the method captures both particle quantity and bio-functional infectivity, resolving the contradiction between particle detection accuracy and infectivity information.
3Measurement precision
If quantitative PCR assay is used to determine viral genome copy number, then the titer can be accurately reflected, but it cannot detect non-nucleic acid bio-functional parameters and is highly sensitive to contamination
Solution Approach 1:
The patent introduces flow cytometry as an intermediary detection method between nucleic acid extraction/PCR and final titer determination. This intermediary system provides physical separation and direct optical detection of individual viral particles, allowing assessment of bio-functional characteristics without the contamination sensitivity inherent in PCR. The flow cytometry acts as a mediator that validates PCR results while adding independent detection capabilities.
Solution Approach 2:
The patent uses fluorescent markers and detection systems to create optical copies or representations of viral particle characteristics. By detecting fluorescent signals from labeled viral components (nucleic acids, proteins, lipids) on individual particles, the method creates detectable copies of viral attributes without requiring amplification steps that are sensitive to contamination, thus maintaining quantification accuracy while reducing contamination sensitivity.
4Adaptability or versatility
If single particle analysis method is implemented, then comprehensive quality assessment is achieved, but the method requires fluorescence labeling reagents and flow particle analyzer
Solution Approach 1:
The patent employs flow cytometry, a universal detection platform, to simultaneously assess multiple quality parameters of viral nucleic acid vectors including particle concentration, size distribution, nucleic acid content, protein markers, and bio-functional infectivity. This single instrument performs multiple functions that would traditionally require separate assays, achieving comprehensive quality assessment without proportionally increasing device complexity.
Solution Approach 2:
The patent utilizes parameter changes in fluorescent signal detection to differentiate and quantify various viral sub-populations. By adjusting detection parameters (fluorescence intensity thresholds, scatter properties, temporal characteristics), the system adapts to measure different quality attributes. This parameter-based flexibility enables comprehensive quality assessment using a single detection system, resolving the contradiction between assessment comprehensiveness and device complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables accurate, efficient, and repeatable detection of bio-functional titers of viral nucleic acid vectors, providing a comprehensive quality assessment that surpasses traditional methods.
Implementation Method 1
preparing a fluorescence labeling reagent that can specifically bind to the viral nucleic acid vector
Implementation Method 2
detecting the sample solution comprising the viral nucleic acid vector by a flow particle analyzer, and recording data in a scattering channel and/or fluorescence channel
Data Source
AI summary
The present disclosure relates to a method for analyzing one or more parameters of a viral nucleic acid vector, and belongs to the field of biological technology. The method may optionally comprise preparing a particle size standard curve and/or a concentration standard solution for the viral nucleic acid vector to measure the particle size and the concentration thereof. The method comprises preparing a specific target recognition reagent conjugated to a fluorescence labeling reagent for the parameters of the viral nucleic acid vector, detecting a sample by a flow particle analyzer, and the like. The method enables a deeper analysis of the “viral titer” obtained by traditional approaches, yielding more accurate detection results, which is of significant importance for downstream release decisions, process control, and the evaluation of clinical safety.